A detailed history of Morgan Stanley transactions in Aim Immuno Tech Inc. stock. As of the latest transaction made, Morgan Stanley holds 85,320 shares of AIM stock, worth $36,687. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,320
Previous 77,318 10.35%
Holding current value
$36,687
Previous $34,000 17.65%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.33 - $0.48 $2,640 - $3,840
8,002 Added 10.35%
85,320 $40,000
Q4 2023

Feb 13, 2024

SELL
$0.4 - $0.56 $70,000 - $98,000
-175,000 Reduced 69.36%
77,318 $34,000
Q3 2023

Nov 15, 2023

SELL
$0.44 - $0.71 $80,625 - $130,100
-183,240 Reduced 42.07%
252,318 $116,000
Q2 2023

Aug 14, 2023

SELL
$0.4 - $0.67 $70,007 - $117,262
-175,019 Reduced 28.66%
435,558 $291,000
Q1 2023

May 15, 2023

SELL
$0.32 - $0.77 $97,943 - $235,675
-306,072 Reduced 33.39%
610,577 $262,000
Q4 2022

Feb 14, 2023

SELL
$0.31 - $0.6 $149,358 - $289,080
-481,800 Reduced 34.45%
916,649 $284,000
Q3 2022

Nov 14, 2022

SELL
$0.57 - $0.81 $114,487 - $162,692
-200,855 Reduced 12.56%
1,398,449 $814,000
Q2 2022

Oct 27, 2022

SELL
$0.78 - $1.27 $306,403 - $498,887
-392,825 Reduced 19.72%
1,599,304 $1.25 Million
Q2 2022

Aug 15, 2022

SELL
$0.78 - $1.27 $306,403 - $498,887
-392,825 Reduced 19.72%
1,599,304 $1.25 Million
Q1 2022

Oct 27, 2022

BUY
$0.67 - $1.18 $263,192 - $463,533
392,825 Added 24.56%
1,992,129 $2.11 Million
Q1 2022

May 13, 2022

SELL
$0.67 - $1.18 $32,999 - $58,118
-49,253 Reduced 2.41%
1,992,129 $2.11 Million
Q4 2021

Feb 14, 2022

SELL
$0.92 - $1.96 $315,557 - $672,274
-342,997 Reduced 14.39%
2,041,382 $1.88 Million
Q3 2021

Nov 15, 2021

BUY
$1.91 - $2.17 $4.55 Million - $5.17 Million
2,384,379 New
2,384,379 $4.82 Million

Others Institutions Holding AIM

About AIM ImmunoTech Inc.


  • Ticker AIM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,049,300
  • Market Cap $20.7M
  • Description
  • AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...
More about AIM
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.